MEDIA RELEASE
THURSDAY, 26TH AUGUST 2004

CELLSPRAY® PRODUCTS APPROVED FOR UNITED KINGDOM & CORPORATE OFFICE TO MOVE TO CAMBRIDGE

Thursday 26th August 2004, PERTH, AUSTRALIA: Clinical Cell Culture Ltd (C3, ASX: CCE) today announced that the British Medicines and Healthcare products Regulatory Agency has authorised the supply of CellSpray® XP and CellSpray® in the United Kingdom.

Clinical Cell Culture Chief Executive Officer Troels Jordansen said the authorisation was an important step for C3 and a milestone in the Company's plan for product commercialisation in Europe.

"Due to its long history of skin grafting and development of new methods of skin culture, the UK provides a strong potential market for our products," Troels Jordansen said.

"The authorisation recognises the secure and innovative nature of our products. Although procedures are well established in the UK, cultured skin is mainly supplied through a limited number of hospital laboratories satisfying their own local needs."

In recognition of the importance of the European and UK market, C3 will relocate most of its corporate activities from Perth to the UK to a new corporate office in Cambridge.

"Being closer to our main markets will boost our regulatory approvals process and allow us to finetune our launch activities with our distributors across Europe."

"Having a significant presence in Europe will also allow C3 to optimise sales and maintain close contact with customers," Troels Jordansen added.

This UK authorisation is the 6th for CellSpray® products in Europe and follows earlier C3 announcements on national approvals from:

- Germany
- Austria
- The Netherlands
- Switzerland (XP only)
- Denmark (clinical trial usage)

C3 will continue its presence in Australia, by remaining listed on the Australian Stock Exchange and continue to have a majority of Australian based directors. C3 will also maintain its Research & Development activities in Perth. C3 is currently in the early stages of developing EpiGrow®, an autologous skin derived fluid for the treatment of chronic wounds. C3 will also continue to manage its Clinical Affairs and Asia Pacific commercial activities from Perth.

C3 announced on 6th July 2004, that the Belgium Health Authorities have provided GMP approval letter for Cambrex to produce CellSpray® products. C3 is currently finalising the last steps of the planned post approval validation and expects to treat in the near future its first CellSpray® patient within Europe.

ENDS

FOR FURTHER INFORMATION PLEASE CONTACT:

Troels Jordansen or Gabriel Chiappini
Clinical Cell Culture
Tel: +61 (0)8 9355 6288
Email: investor@clinicalcellculture.com

Claire Stannard
Porter Novelli
Tel: +61 (0)8 9386 1233
Mob: +61 (0) 409 189 410

ABOUT C3

Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/collection technology, C3 is able to provide innovative treatment solutions, using the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

The company's lead products are CellSpray®, a suspension containing cultured skin cells from the patient for use in the treatment of major burns and scars, and ReCell®, a device that enables the collection of healthy skin cells for immediate application on damaged skin such as small burns, areas of pigment loss and scars. C3's products have been used on more than 1,600 patients to date.

C3 is focused on further research and development. Pipeline products evolving from our R&D programme include EpiGrow®, an autologous skin derived fluid for the treatment of chronic wounds and SteriFast®, an end-point sterility diagnostic system that will allow testing of biological products within hours, compared to current technologies which can take several days.

C3 is currently internationalising its business by seeking regulatory approvals for its products throughout Asia-Pacific, Europe and USA. Regionalised commercial support staff will support the launch activities and will be supplemented through a global network of independent distributors/agents.